Diabetic Neuropathy - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 114 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diabetic Neuropathy - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Diabetic Neuropathy - Pipeline Review, H1 2015', provides an overview of the Diabetic Neuropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diabetic Neuropathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Neuropathy Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Neuropathy - Overview 10
Pipeline Products for Diabetic Neuropathy - Comparative Analysis 11
Diabetic Neuropathy - Therapeutics under Development by Companies 12
Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes 14
Diabetic Neuropathy - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Diabetic Neuropathy - Products under Development by Companies 18
Diabetic Neuropathy - Products under Investigation by Universities/Institutes 20
Diabetic Neuropathy - Companies Involved in Therapeutics Development 21
Acorda Therapeutics, Inc. 21
Araim Pharmaceuticals Inc. 22
Astellas Pharma Inc. 23
Cebix Incorporated 24
Eli Lilly and Company 25
Glucox Biotech AB 26
Longevity Biotech, Inc 27
Lpath, Inc. 28
Neuralstem, Inc. 29
Omeros Corporation 30
Pfizer Inc. 31
R-Tech Ueno, Ltd. 32
Spinifex Pharmaceuticals Pty Limited 33
Sumitomo Dainippon Pharma Co., Ltd. 34
Virobay Inc. 35
ViroMed Co., Ltd. 36
Diabetic Neuropathy - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
Antimunocel - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ARA-290 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ASP-8477 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BBI-21007 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Biologic for Diabetic Nephropathy - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BNV-222 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
capsaicin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CBX-129801 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Cyndacel-M - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drug for Peripheral Neuropathic Pain and Diabetic Peripheral Neuropathy - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
EMA-401 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ketoprofen - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Lpathomab - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
NRD-135SE1 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NSI-566 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
OMS-721 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
PF-05089771 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ranirestat - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
RTU-1096 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecules for Diabetic Neuropathy - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Synthetic Peptides for Central Nervous System Disorders and Diabetic Neuropathy - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
VBY-285 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
VM-202 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Diabetic Neuropathy - Recent Pipeline Updates 84
Diabetic Neuropathy - Dormant Projects 100
Diabetic Neuropathy - Discontinued Products 104
Diabetic Neuropathy - Product Development Milestones 106
Featured News & Press Releases 106
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 106
Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 107
Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 108
Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting 109
Sep 07, 2011: Cebix To Chair Symposium On C-Peptide And Pathophysiology Of Diabetes At EASD Annual Meeting 109
May 11, 2011: Dainippon Sumitomo Pharma Announces Results Of Phase II Clinical Trial For Ranirestat For Diabetic Complications 110
Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial 111
Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy 111
Sep 29, 2005: Dainippon And Eisai Signs Licensing Agreement For A Potential New Treatment For Diabetic Neuropathy 111
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 113
Disclaimer 114

List of Tables

Number of Products under Development for Diabetic Neuropathy, H1 2015 10
Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Diabetic Neuropathy - Pipeline by Acorda Therapeutics, Inc., H1 2015 21
Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals Inc., H1 2015 22
Diabetic Neuropathy - Pipeline by Astellas Pharma Inc., H1 2015 23
Diabetic Neuropathy - Pipeline by Cebix Incorporated, H1 2015 24
Diabetic Neuropathy - Pipeline by Eli Lilly and Company, H1 2015 25
Diabetic Neuropathy - Pipeline by Glucox Biotech AB, H1 2015 26
Diabetic Neuropathy - Pipeline by Longevity Biotech, Inc, H1 2015 27
Diabetic Neuropathy - Pipeline by Lpath, Inc., H1 2015 28
Diabetic Neuropathy - Pipeline by Neuralstem, Inc., H1 2015 29
Diabetic Neuropathy - Pipeline by Omeros Corporation, H1 2015 30
Diabetic Neuropathy - Pipeline by Pfizer Inc., H1 2015 31
Diabetic Neuropathy - Pipeline by R-Tech Ueno, Ltd., H1 2015 32
Diabetic Neuropathy - Pipeline by Spinifex Pharmaceuticals Pty Limited, H1 2015 33
Diabetic Neuropathy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 34
Diabetic Neuropathy - Pipeline by Virobay Inc., H1 2015 35
Diabetic Neuropathy - Pipeline by ViroMed Co., Ltd., H1 2015 36
Assessment by Monotherapy Products, H1 2015 37
Number of Products by Stage and Target, H1 2015 39
Number of Products by Stage and Mechanism of Action, H1 2015 41
Number of Products by Stage and Route of Administration, H1 2015 43
Number of Products by Stage and Molecule Type, H1 2015 45
Diabetic Neuropathy Therapeutics - Recent Pipeline Updates, H1 2015 84
Diabetic Neuropathy - Dormant Projects, H1 2015 100
Diabetic Neuropathy - Dormant Projects (Contd..1), H1 2015 101
Diabetic Neuropathy - Dormant Projects (Contd..2), H1 2015 102
Diabetic Neuropathy - Dormant Projects (Contd..3), H1 2015 103
Diabetic Neuropathy - Discontinued Products, H1 2015 104
Diabetic Neuropathy - Discontinued Products (Contd..1), H1 2015 105